A Safety, Tolerability, and Pharmacokinetics Study of LY3451838 in Healthy Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs LY-3451838 (Primary) ; LY-3451838 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 02 Dec 2019 Planned End Date changed from 12 Feb 2020 to 27 Feb 2020.
- 02 Dec 2019 Planned primary completion date changed from 12 Feb 2020 to 27 Feb 2020.
- 03 Nov 2019 Status changed from recruiting to active, no longer recruiting.